Abstract
The association of lymphoid neoplasms and antiphospolipid antibodies (APA), with or without thromboembolic complications, has been reported in several cases. We describe one case of B-cell non-Hodgkinís lymphoma (NHL) in which the combination of rituximab with standard chemotherapy led to the complete remission of a severe hypercoagulable state associated with APA.
MeSH terms
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Monoclonal, Murine-Derived
-
Anticoagulants / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Antiphospholipid Syndrome / etiology*
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Heparin / therapeutic use
-
Humans
-
Immunotherapy*
-
Lymphoma, B-Cell / complications
-
Lymphoma, B-Cell / drug therapy*
-
Lymphoma, B-Cell / immunology
-
Lymphoma, B-Cell / surgery
-
Male
-
Middle Aged
-
Prednisone / administration & dosage
-
Pulmonary Embolism / drug therapy
-
Pulmonary Embolism / etiology
-
Recurrence
-
Remission Induction
-
Rituximab
-
Splenectomy
-
Thrombophilia / drug therapy
-
Thrombophilia / etiology*
-
Thrombophlebitis / drug therapy
-
Thrombophlebitis / etiology
-
Vincristine / administration & dosage
-
Warfarin / therapeutic use
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Anticoagulants
-
Rituximab
-
Vincristine
-
Warfarin
-
Doxorubicin
-
Cyclophosphamide
-
Heparin
-
Prednisone